ArticleScientific reports2025
Development and validation of a methylation-specific droplet digital PCR multiplex for lung cancer detection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Single-cell analysis reveals an endothelial TP53-CXCL14 axis in breast cancer progression.Journal of translational medicine · 2026Article
- Prognostic performance of a novel multiplex circulating tumor DNA assay for lung cancer outcomes.Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers are increasingly used in cancer management, including lung cancer. The use of circulating tumour DNA (ctDNA) detection has attracted significant interest as a non-invasive, highly specific, and sensitive strategy. In this study, we developed and validated a methylation-specific droplet digital PCR (ddPCR) multiplex assay with five tumour-specific methylation markers identified by in silico analysis for lung cancer detection across various clinical settings. The performance of the ddPCR multiplex was validated in tissue and plasma in cohorts of healthy controls and patients with both non-metastatic and metastatic disease by examining sensitivity, specificity, and marker dynamics. Furthermore, two different cut-off methods to determine ctDNA-status and their effects on sensitivity and specificity were examined. In non-metastatic disease, the ddPCR multiplex showed ctDNA-positive rates of 38.7% and 46.8%, respectively, with the two cut-off methods. In metastatic cases, these rates increased to 70.2% and 83.0%. Higher sensitivities were observed for small cell lung cancer and squamous cell carcinoma. Analyses of longitudinal samples from patients with metastatic disease undergoing treatment indicated a potential use in prognostication and treatment guidance. We present a robust, cost-effective approach to lung cancer detection. Moving forward, its performance should be evaluated and validated in larger patient cohorts across a range of clinical scenarios, exploring its full potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.